Our results demonstrated that TGF-β was significantly decreased in ND or relapsed-refractory AML patients, and significantly elevated after chemotherapy, which implied that TGF-β may play a positive effect in AML progress. The gene discussed is TGFB1; the disease is acute myeloid leukemia.